Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Seqwell Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are being handled by 2 distinct examiners but are both located within 1 distinct art unit. RAYMONDA, MATTHEW HAROLD is the busiest examiner for the portfolio, with 1 pending office action.
The concentration of 2 pending office actions in 1 distinct art unit suggests that the company's current biotechnology matters are technically related and fall under the same administrative group. However, the involvement of 2 distinct examiners means the company must address 2 different sets of individual preferences. The busiest examiner, RAYMONDA, MATTHEW HAROLD, is responsible for 1 of the 2 pending actions.
For the practitioner, this structure provides 2 independent chances for allowance within a single specialized unit. While the procedural rules of the 1 distinct art unit will be consistent, the company must still navigate the unique feedback of 2 distinct examiners. This balance of art unit concentration and examiner diversity allows for a focused yet varied approach to the 2 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAYMONDA, MATTHEW HAROLD | 1 | 40.0% | +47.7% |
| BOESEN, CHRISTIAN C | 1 | 76.0% | +21.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697064 | KITS AND METHODS FOR PREPARATION OF NUCLEIC ACID LIBRARIES FOR SEQUENCING | RAYMONDA, MATTHEW HAROLD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18697064 | KITS AND METHODS FOR PREPARATION OF NUCLEIC ACID LIBRARIES FOR SEQUENCING | RAYMONDA, MATTHEW HAROLD | — |
| 18025343 | SEQUENCING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | BOESEN, CHRISTIAN C | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18697064 | KITS AND METHODS FOR PREPARATION OF NUCLEIC ACID LIBRARIES FOR SEQUENCING | RAYMONDA, MATTHEW HAROLD | — | §103§112 | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18025343 | SEQUENCING OLIGONUCLEOTIDES AND METHODS OF USE THEREOF | BOESEN, CHRISTIAN C | 1684 | §102 | Non-Final OA | — | Pending | Mar 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSeqwell Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Matthew Harold Raymonda has the most, with 1 of Seqwell Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.